Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
acrizanib
- Development stage
- Phase 2
- Lead developer
- Novartis
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Administration
- Intravitreal, Ophthalmic
01
Overview
Acrizanib is a small molecule tyrosine kinase inhibitor that selectively targets vascular endothelial growth factor receptor 2 (VEGFR2). It is being investigated as a treatment for neovascular (wet) age-related macular degeneration and other ocular diseases characterized by pathological angiogenesis. Acrizanib works by binding to the intracellular domain of VEGFR2, inhibiting its phosphorylation and downstream signaling pathways, thereby suppressing abnormal blood vessel formation in the eye. Preclinical studies have shown that intravitreal injection of acrizanib reduces pathological neovascularization, inflammation, and vascular leakage without significantly affecting normal physiological angiogenesis or retinal thickness. The drug has completed Phase 2 clinical trials for neovascular age-related macular degeneration[1][3][4][5][7].
- Other names
- acrizanib [INN]
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on acrizanib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on acrizanib.